anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PURPOSE: There is limited evidence concerning the computed tomography (CT) follow-up interval to detect recurrence and second primary cancers after surgery for non-small-cell lung cancer (NSCLC). In this study, we aimed to investigate the impact of CT interval on survival after surgery.
METHODS: This retrospective study analyzed the prognosis of 103 patients who underwent periodic CT after complete resection for pathological stage II-III NSCLC at a single institute between 2015 and 2020. The patients were stratified based on the follow-up CT intervals into the half-year group (Group H) and annual group (Group A). Additionally, the underlying differences in clinical backgrounds between the 2 groups were adjusted by propensity score matching.
RESULTS: A total of 103 patients (Group H, 76 patients; Group A, 27 patients) were included in this study. The 5-year overall survival (OS) rates in the unmatched cohort were 83.5% and 95.2% in groups H and A, respectively ( P = 0.17). Among the matched cohort, 42 and 21 patients were in groups H and A. The 5-year OS rates of the matched cohort were 89.8% and 94.4% in groups H and A ( P = 0.45), with no significant difference.
CONCLUSIONS: There was no association between CT intervals and postoperative survival.
Hereditary cardiomyopathies (CMPs), including arrhythmogenic cardiomyopathy (ACM), dilated cardiomyopathy (DCM), and hypertrophic cardiomyopathy (HCM), represent a group of heart disorders that significantly contribute to cardiovascular morbidity and mortality and are often driven by genetic factors. Recent advances in next-generation sequencing (NGS) technology have enabled the identification of rare variants in both well-established and minor genes associated with CMPs. Nowadays, a set of core genes is included in diagnostic panels for ACM, DCM, and HCM. On the other hand, despite their lesser-known status, variants in the minor genes may contribute to disease mechanisms and influence prognosis. This review evaluates the current evidence supporting the involvement of the minor genes in CMPs, considering their potential pathogenicity and clinical significance. A comprehensive analysis of databases, such as ClinGen, ClinVar, and GeneReviews, along with recent literature and diagnostic guidelines provides a thorough overview of the genetic landscape of minor genes in CMPs and offers guidance in clinical practice, evaluating each case individually based on the clinical referral, and insights for future research. Given the increasing knowledge on these less understood genetic factors, future studies are essential to clearly assess their roles, ultimately leading to improved diagnostic precision and therapeutic strategies in hereditary CMPs.
A major risk factor for ischemic heart disease is advanced age. In adult bone marrow and other tissues, the number and function of stem cells decline with aging. Telomerase reverse transcriptase (TERT) is a nuclear protein that decreases senescence. Myocardin (MYOCD) is a transcription factor for myogenesis. Thus a method is provided for the simultaneous delivery of the telomerase reverse transcriptase (TERT) and myocardin MYOCD genes that resuscitates mesenchymal stromal cells (MSCs) from aged adipose and bone marrow tissues by increasing their capacity for survival, proliferation, and differentiation. TERT + /MYOCD +  MSCs restores a capacity for repairing ischemic tissues via improved blood flow and revascularization.
All sampled patients will administer STAI-1 and then VAS before relaxation exercises. Pain levels will be evaluated by applying VAS again. VAS and STAI will applie again to all patients at discharge. 400 mg contramol in 100 cc SF at 5cc/hour continues on the first day after surgery by PCA (Patient control analgezia). The total number of boluse administrations and additional analgesic requirements of the patients will record by PCA after the application during the day. After the implementation of the PMR exercise protocol, no side effects or signs of discomfort will observe in the patients. In the hospital where the study will conduct, if patients can tolerate it, they are routinely mobilized for 8 hours after surgery and are fed there 6 hours later. Patients in the experimental and control groups will evaluate in terms of postoperative mobilization and oral feeding initiation times.
The present invention relates to the identification of CTL epitopes by the combination of biochemical assays, statistical matrix calculations, and artificial neural networks. A set of peptide libraries are used to generate complete unbiased matrices representing peptide-MHC interactions used to generate a primary prediction of MHC binding for all possible non-redundant peptides. The best binders are subject to a quantitative biochemical binding assay and subsequently a computerised artificial neural network prediction program built from these in vitro experimental MHC-I binding data. The method further comprises improving the identified epitope by replacing amino acids, and testing the identified CTL epitopes in in vitro and in vivo models. Thus, one aspect of the invention relates to the identification of a CTL component of a vaccine and the development of said CTL component. Another aspect of the invention relates to the identified epitopes of said CTL component.
Participants received rivaroxaban 5 mg bid and aspirin placebo od. All doses were provided in tablet form for oral administration. Participants who did not have a continuous need to take a PPI, were additionally randomized 1:1 to receive pantoprazole 40 mg (tablet form for oral administration, od) or matching placebo od. Participants who consented to LTOLE part received open label rivaroxaban 2.5 mg bid and aspirin 100 mg od in LTOLE part.
Provided herein are rumen-protected compositions. The compositions include coated rumen-protected compositions which comprise a coating and a bioactive core comprising a physiologically active ingredient. The coating includes a chitosan organic salt, an emulsifier, and a fatty acid source. Further provided are rumen-protected pellet compositions, which may optionally comprise a coating. The pellet compositions include a bioactive core comprising a physiologically active ingredient and a chitosan organic salt. Further provided are methods of making the compositions and methods of delivering methionine to an animal.
Healthy patients between the ages of 18-75 who have been diagnosed with moderate to severe Trigeminal Neuralgia Pain. The study team will perform transcranial electrical brain stimulation using either electrodes that are in the form of two salt-water soaked sponges attached to the head or a set of smaller gel-covered disk electrodes that fit inside the electrode holders of the EEG cap. During stimulation a weak direct or alternating current will be passed through the stimulating electrodes. Stimulation may last 20 to 30 minutes.
The present disclosure provides methods and systems for improved rehabilitation of ankle motion by visually-driven priming of motor movement. The methods and systems include a sensor configured to measure ankle angle. The generated signal may be used to determine a maximal range of angles the user is capable of generating in order to calibrate the system. Subsequently, the signal from the sensor may be used to display the user location relative to an indication used to prime the motor movement. User performance may be tracked and performance-based awards given to increase rehabilitative outcome. The method and systems may encourage increased patient compliance by providing a comfortable, effective mode of ankle rehabilitation.
Upon arriving to the study, participants will complete baseline measures assessing for the inclusion and exclusion criteria, as well as baseline alcohol craving and subjective response measures. Participants will then be randomly assigned into the active treatment (exercise) or distraction (coloring) condition. After randomization, participants will consume a low-dose alcohol beverage (BAC=0.03g/dL; equivalent to approximately 1 standard alcohol beverage) within five minutes to induce active alcohol craving. 15 minutes post-beverage consumption, participants will complete the alcohol craving and subjective response measures. At 20 minutes post-beverage consumption, participants will begin their randomly assigned 20-minute activity (exercise or coloring). At approximately 12 minutes into the activity (32 minutes post beverage consumption) and immediately after the activity (44 minutes post beverage consumption), the participants will complete the alcohol craving and subjective response measures. Participants will then be given a tray of three 8oz. cups of water and 3 8oz. cups of an alcohol-placebo beverage and will be allowed to drink as much or as little of the beverages as they would like.
A series of new 4,6-diamino-1,2-dihydro-1-aryl-2-(-tricyclo[3.3.1.1 3,7 ]decyl]-1,3,5-triazines where the aryl group is a substituted or unsubstituted phenyl, or naphthyl-group, as pharmaceutically accepted salts or as free bases. The phenyl group substituents are halides, alkyls, alkoxyls or nitro group. One or more of the above substituents are found one or more times each one, and in various positions of the phenyl group. The corresponding isomers, stereoisomers, enantiomers, free bases and their complexes with various natural macromolecules and synthetic derivatives of them. The invention refers to new and prototype compounds inhibiting the proliferation of unwanted cells that belong to pathogenic microorganisms, to human tissues, to pathological cells, or any pathological cell proliferation. It also refers to the synthesis and the method of synthesis of the above mentioned compounds. The synthesis and the method of synthesis thereof of a series characterized by the preparation of the final triazines, by cyclization of the bigouanide hydrochlorides with adamantane-1-carboxaldehyde. Preparation of the inclusion complexes is realized from compexation of the corresponding hydrochlorides of the above mentioned triazines with natural macromolecules or synthetic derivatives.
This is an open-label, randomized (the order in which you receive the treatment sessions is determined by chance, like tossing a coin), crossover (participants will receive different interventions sequentially during the trial) study in healthy participants to investigate the effect of telaprevir 750 mg, every 8 hours, on the pharmacokinetics (how the drug is absorbed into the bloodstream, distributed in the body and eliminated from the body) of raltegravir 400 mg, twice a day, and vice versa. The study population will consist of 20 healthy participants. Each individual participant will receive two treatments: Treatment A (telaprevir 750 mg, every 8 hours, alone, on Days 1 to 6, with a morning dose on Day 7) and Treatment B (raltegravir 400 mg, twice a day, on Days 1 to 10 and telaprevir 750 mg, every 8 hours, on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11). Half of the participants will receive first Treatment A and then Treatment B; the other half will receive first Treatment B and then Treatment A. There will be a washout period of at least 14 days between the 2 sessions. The screening period will be maximum 21 days; the treatment duration will be approximately 4.5 weeks, and the follow-up period will be 30 to 31 days. All study medication will be taken with food. On Day 7 of Treatment A and Day 11 of Treatment B, 9 blood samples will be taken for determination of the levels of telaprevir in the blood. On Days 4 and 11 of Treatment B, 10 blood samples will be taken for determination of the levels of raltegravir in the blood. Predose pharmacokinetic samples will be collected on other days during the treatment sessions. Safety and tolerability will be evaluated throughout the trial by evaluating results of blood and urine analyses, vital signs, physical examinations, electrocardiograms (electrical recording of the heart), drug and alcohol screenings, and by assessing how the participant is feeling. In Treatment A, participants will receive 2 oral tablets of telaprevir 375 mg every 8 hours on Days 1 to 6, with a morning dose on Day 7. In Treatment B, participants will receive 1 oral tablet of 400 mg raltegravir twice a day on Days 1 to 10 and 2 oral tablets of 375 mg telaprevir every 8 hours on Days 5 to 10, with a morning dose of raltegravir, and a morning and afternoon dose of telaprevir on Day 11.
Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most prevalent and dose-limiting complications in chemotherapy patients. One identified mechanism underlying CIPN is neuroinflammation. Most of this research has been conducted in only male or female rodent models, making direct comparisons regarding the role of sex differences in the neuroimmune underpinnings of CIPN limited. Moreover, most measurements have focused on the dorsal root ganglia (DRG) and/or spinal cord, while relatively few studies have been aimed at characterizing neuroinflammation in the brain, for example the periaqueductal grey (PAG). The overall goals of the present study were to determine (1) paclitaxel-associated changes in markers of inflammation in the PAG and DRG in male and female C57Bl6 mice and (2) determine the effect of prophylactic administration of an anti-inflammatory cannabinoid, cannabigerol (CBG). In Experiment 1, male and female mice were treated with paclitaxel (8-32 mg/kg/injection, Days 1, 3, 5, and 7) and mechanical sensitivity was measured using Von Frey filaments on Day 7 (Cohort 1) and Day 14 (Cohort 2). Cohorts were euthanized on Day 8 or 15, respectively, and DRG and PAG were harvested for qPCR analysis of the gene expression of markers of pain and inflammation Aig1, Gfap, Ccl2, Cxcl9, Tlr4, Il6, and Calca. In Experiment 2, male and female mice were treated with vehicle or 10 mg/kg CBG i.p. 30 min prior to each paclitaxel injection. Mechanical sensitivity was measured on Day 14. Mice were euthanized on Day 15, and PAG were harvested for qPCR analysis of the gene expression of Aig1, Gfap, Ccl2, Cxcl9, Tlr4, Il6, and Calca. Paclitaxel produced a transient increase in potency to produce mechanical sensitivity in male versus female mice. Regarding neuroinflammation, more gene expression changes were apparent earlier in the DRG and at a later time point in the PAG. Also, more changes were observed in females in the PAG than males. Overall, sex differences were observed for most markers at both time points and regions. Importantly, in both the DRG and PAG, most increases in markers of neuroinflammation and pain occurred at paclitaxel doses higher than those associated with significant changes in the mechanical threshold. Two analytes that demonstrated the most compelling sexual dimorphism and that changed more in males were Cxcl9 and Ccl2, and Tlr4 in females. Lastly, prophylactic administration of CBG protected the male and female mice from increased mechanical sensitivity and female mice from neuroinflammation in the PAG. Future studies are warranted to explore how these sex differences may shed light on the mechanisms of CIPN and how non-psychoactive cannabinoids such as CBG may engage these targets to prevent or attenuate the effects of paclitaxel and other chemotherapeutic agents on the nervous system.
Liraglutide subcutaneous injection once daily for 26 weeks (starting dose 0.6 mg daily up-titrated to 1.2 mg daily on Day 8). Participants continued their stable dose of metformin \>=1500 mg orally daily. Participants may have had their liraglutide dose uptitrated to 1.8 mg daily for glycemic control.
The initial phase of multiple sclerosis (MS), often known as clinically isolated syndrome (CIS), is a critical period for identifying individuals at high risk of progressing to full-blown MS and initiating timely treatment. In this study, we aimed to evaluate the prognostic value of C-X-C motif chemokine ligand 13 (CXCL13) and interleukin-8 (IL-8) as potential markers for CIS patients' conversion to MS. Our study encompassed patients with CIS, those with relapsing-remitting MS (RRMS), and control subjects, with sample analysis conducted on both cerebrospinal fluid (CSF) and serum. Patients were categorized into four groups: CIS-CIS (no MS development within 2 years), CIS-RRMS (conversion to RRMS within 2 years), RRMS (already diagnosed), and a control group (CG) with noninflammatory central nervous system disorders. Results showed significantly elevated levels of CXCL13 in CSF across all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Although CXCL13 concentrations were slightly higher in the CIS-RRMS group, statistical significance was not reached. Similarly, significantly higher levels of IL-8 were detected in CSF samples from all patient groups compared with the CG (p < 0.0001, Kruskal-Wallis test). Receiver operating characteristic analysis in the CIS-RRMS group identified both CXCL13 (area under receiver operating characteristic curve = .959) and IL-8 (area under receiver operating characteristic curve = .939) in CSF as significant predictors of CIS to RRMS conversion. In conclusion, our study suggests a trend towards elevated CSF IL-8 and CSF CXCL13 levels in CIS patients progressing to RRMS. These findings emphasize the importance of identifying prognostic markers to guide appropriate treatment strategies for individuals in the early stages of MS.
Multiple large series conducted in hospitalized patients have reported high rates of myocardial injuries in the acute stage of COVID-19 infection. These findings have raised concerns regarding potential long term consequences of the pandemic on cardiovascular diseases (heart failure and sudden cardiac deaths due to scar-related arrhythmias). However, the prevalence of silent myocardial injuries in the general population who presented a COVID-19 infection managed without hospitalization are unknown. In addition, the propensity of these scars to generate arrhythmias have not been thoroughly studied. COVID CMR will include 120 patients with history of laboratory-proven symptomatic COVID-19 infection managed without hospitalization and 120 age- and sex-matched controls. At day 1, all subjects will undergo a 12-lead electrocardiogram, a contrast-enhanced CMR study including advanced methods to detect silent myocardial scars, and a blood sample to look for markers of inflammation and cardiac injury, and to assess the COVID-19 serological status at the time of the CMR study. The prevalence of myocardial scars on CMR will be compared between the 2 groups. In a second visit at 3 months, patients showing myocardial scar on CMR will be matched to healthy volunteers showing no such scars, and these 2 population subsets will undergo exercise electrocardiogram (ECG) and 24 hour Holter ECG to characterize the arrhythmogenic role of silent myocardial scars.
As women across North America and Europe increasingly delay childbirth, fertility preservation is emerging as an important issue among young breast cancer patients. The dramatic increase in survival for the major pediatric cancers in the last 50 years has resulted in an expanding population of childhood cancer survivors. The information currently available to counsel these patients about the impact of treatment on their fertility is inadequate. A significant degree of subfertility can exist prior to the onset of frank ovarian failure, and current studies do not address this.

This study will adopt new technologies that have revolutionized the evaluation of female fertility to assess ovarian function in young breast cancer survivors. The results will provide new, more accurate and clinically useful information to patients and physicians about the impact of cancer therapy on fertility. The results have the potential to influence clinical decisions regarding cancer treatment, and the use of assisted reproductive technologies for contemporary patients and survivors. Further, insofar as treatment advances are designed to improve disease control while reducing toxicity, these results may serve as the basis for better understanding the toxicity of modern therapy and provide opportunities for improvement.
The control arm, i.e. FPS not a part of the treatment shops, will continue to receive the regular rice supplied by the Public Distribution System (PDS), and members of households sampled for baseline will have blood samples and demographic surveys taken at a baseline visit, and another visit at 12-15 months after the baseline visit. It therefore represents the status quo and serves as a control group against which any improvements observed in the treatment group will be gauged.
PURPOSE: To simply detect an iso thiazolone compound at a high speed at a low cost by using an immunogen complex with a polymer carrier covalently bonded to iso thiazolones having a reactive group. CONSTITUTION: A polymer carrier is covalently bonded to iso thiazolones having a reactive group to obtain an immunogen complex. The iso thiazolone is 2- methyl-3-iso thiazolone. The obtained immunogenic complex applies immunity to an animal, e.g. a mouse, antibody producing cells are obtained from the animal, and the cells are fused with tumor cells to obtain hybridoma. At least one hybridoma capable of generating the antigen peculiarly bonded with iso thiazolones is selected from the obtained hybridoma. The antigen generated from the selected hybridoma is recovered, and the monoclonal antibody having the reactivity with iso thiazolones is obtained.
The invention comprises compounds of the formula <FORM:0985658/C2/1> wherein R1 and R2 each represent a halogen atom or an alkyl, alkoxy, alkylthio, nitro, trifluoromethyl, carboxy, alkoxycarbonyl, carbamyl or cyano group but at least one of which is a carboxy, alkoxycarbonyl, carbamyl or cyano group and wherein the broken lines denote that the groups attached thereby are optional.  The carboxy substituted benzophenones may be prepared from the corresponding methyl substituted benzophenones and acylated to yield a methyl substituted 2-acetamido-benzophenone, which may be oxidized to a carboxy-substituted 2-acetamide benzophenone.  The latter may be hydrolysed to a carboxy-substituted 2-amino benzophenone.  The carboxy groups may be esterified, or converted to carbamyl by dehydration of the ammonium salt of the carboxylic acid.  The carbamyl compounds may be converted to cyano derivaties by dehydration (e.g. by treatment with POCl3).
FIELD: pharmaceutical industry.SUBSTANCE: group of inventions refers to granules for traditional Chinese medicine and to a method for production thereof. Method of producing granules for traditional Chinese medicine, wherein the raw medicinal substances include: 400 pts. wt. Radix Ginseng, 400 pts. wt. Poria, 400 pts. wt. fried with bran Rhizoma Atractyldis Macrocephalae, 400 pts. wt. Rhizoma Dioscoreae, 300 wt part fried Semen Dolichoris Album, 200 pts. wt. Semen Nelumbinis, 200 pts. wt. Semen Coicis fried with bran, 200 pts. wt. Fructus Amomi Villosi, 200 pts. wt. Radix Platycodonis and 400 pts. wt. Radix Glycyrrhizae, where the method of obtaining involves certain stages (versions). Method of administering a granule produced by the above methods involves administering a granule to a child suffering from diarrhea, where child is 3–5 years old, introduction is carried out 3 times day on 1 g for once, and to child of 5–14 years introduction is carried out 3 times day on 2 g at once. Use of the granule obtained using the above methods for preparing a drug for treating a child suffering from diarrhea.EFFECT: above described methods enable to obtain safe granules for traditional Chinese medicine, with good solubility, good taste, high acceptability for children, high content of polysaccharides.9 cl, 6 tbl, 5 ex